Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 28, Issue 20, p.3330-5 (2010)


2010, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Benzenesulfonates, Carcinoma, Squamous Cell, Center-Authored Paper, Disease-Free Survival, Drug Evaluation, Female, Head and Neck Neoplasms, Humans, Male, Middle Aged, Neoplasm Metastasis, Public Health Sciences Division, Pyridines


We conducted a phase II trial to evaluate the efficacy and safety of single-agent sorafenib in chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN). The primary end point was response probability (ie, confirmed complete and partial response [PR]).